AA
AVDL

ALPS Advisors’s Avadel Pharmaceuticals AVDL Stock Holding History

ALPS Advisors’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-70,933
Closed -$311K – 883
2018
Q3 		$311K Buy
70,933
+12,762
+22% +$68.9K ﹤0.01% 896
2018
Q2 		$357K Buy
58,171
+4,411
+8% +$30.9K ﹤0.01% 823
2018
Q1 		$392K Buy
53,760
+9,342
+21% +$82.2K ﹤0.01% 795
2017
Q4 		$364K Buy
44,418
+4,942
+13% +$46.3K ﹤0.01% 702
2017
Q3 		$414K Buy
39,476
+2,251
+6% +$21.5K ﹤0.01% 693
2017
Q2 		$411K Buy
+37,225
New +$374K ﹤0.01% 672

Other funds holding AVDL

BIP
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

ALPS Advisors's AVDL Position: Q4 2018 in Review

ALPS Advisors sold out of Avadel Pharmaceuticals (AVDL) in Q4 2018, closing a stake of 70,933 shares — an estimated $311K sold.

ALPS Advisors first reported a position in AVDL in Q2 2017 and held it in 6 quarters. The position peaked at $414K in Q3 2017. 59 funds tracked by Wall St. Rank hold AVDL as of Q4 2018.

  • ALPS Advisors reported no remaining Avadel Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • ALPS Advisors sold 70,933 Avadel Pharmaceuticals shares in Q4 2018, an estimated $311K.
  • ALPS Advisors first reported a position in Avadel Pharmaceuticals in Q2 2017 and held it in 6 quarters.
  • ALPS Advisors's Avadel Pharmaceuticals position peaked at $414K in Q3 2017.
  • 59 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q4 2018.

Based on ALPS Advisors's 13F filing for Q4 2018, filed 4 Feb 2019.